Streetbeat News

Analyst Ratings

RVLV

Revolve Group, Inc. (NYSE:RVLV) reported Q4 earnings surpassing estimates with earnings of 5 cents per share against expected 2 cents, and sales of $257.78 million versus the anticipated $246.38 million. Following the report, analysts from Needham, Wedbush, and Raymond James adjusted their price targets upwards, reflecting optimism about the company's performance despite a challenging consumer discretionary spending environment. Revolve Group's shares rose 3.1% to close at $17.49.

Portfolio Pulse from Avi Kapoor

February 28, 2024 | 1:30 pm

GUTS

Evercore ISI Group analyst Umer Raffat initiates coverage on Fractyl Health (NASDAQ:GUTS) with an Outperform rating, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:29 pm

IMAX

Wedbush analyst Alicia Reese reiterated an Outperform rating on Imax (NYSE:IMAX) and maintained a $22 price target.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:23 pm

AAPL

Wedbush analyst Daniel Ives has reiterated an Outperform rating on Apple (AAPL) and maintained a $250 price target.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:21 pm

AZO

Wedbush analyst Seth Basham maintains an Outperform rating on AutoZone (NYSE:AZO) and raises the price target from $2950 to $3400, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:18 pm

LOW

Wedbush analyst Seth Basham maintains a Neutral rating on Lowe's Companies (NYSE:LOW) and raises the price target from $215 to $250.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:13 pm

RVLV

Wedbush analyst Tom Nikic has maintained a Neutral rating on Revolve Group (RVLV) but raised the price target from $12 to $17.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:11 pm

KURA

Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Kura Oncology (NASDAQ:KURA) and maintained a $37 price target.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:08 pm

ANF

APLS

AXON

ECL

ESS

IAS

ICUI

STRL

TARS

TREE

Top Wall Street analysts have updated their price targets and ratings for several US-listed companies, including Tarsus Pharmaceuticals, Apellis Pharmaceuticals, Axon Enterprise, Essex Property Trust, Integral Ad Science Holding Corp, Sterling Infrastructure, LendingTree, ICU Medical, Ecolab, and Abercrombie & Fitch. These changes reflect analysts' latest views on these companies, with adjustments made based on various factors such as company performance and market conditions.

Portfolio Pulse from Avi Kapoor

February 28, 2024 | 1:07 pm

VRDN

Wedbush analyst Laura Chico maintains an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) and raises the price target from $39 to $40.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:07 pm